Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03553836




Registration number
NCT03553836
Ethics application status
Date submitted
1/06/2018
Date registered
12/06/2018
Date last updated
21/08/2024

Titles & IDs
Public title
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Scientific title
Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Secondary ID [1] 0 0
MK-3475-716
Secondary ID [2] 0 0
3475-716
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Pembrolizumab
Other interventions - Placebo

Experimental: Pembrolizumab - Participants receive 200 mg pembrolizumab (2 mg/kg for a maximum of 200 mg in pediatric participants) by intravenous (IV) infusion once every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to \~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of pembrolizumab and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2.

Placebo comparator: Placebo - Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to \~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2.


Treatment: Other: Pembrolizumab
Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Other interventions: Placebo
Administered as an IV infusion every 3 weeks (Q3W)
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recurrence-free Survival (RFS)
Timepoint [1] 0 0
Up to ~32.7 months
Secondary outcome [1] 0 0
Distant Metastasis-free Survival (DMFS)
Timepoint [1] 0 0
Up to ~9 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to ~15 years
Secondary outcome [3] 0 0
Number of Participants Who Experienced at Least One Adverse Event (AE)
Timepoint [3] 0 0
Up to ~19.3 months
Secondary outcome [4] 0 0
Number of Participants Who Discontinued Study Treatment Due to an AE
Timepoint [4] 0 0
Up to ~19.3 months

Eligibility
Key inclusion criteria
Inclusion:

* Has surgically resected and histologically/pathologically confirmed new diagnosis of Stage IIB or IIC cutaneous melanoma per American Joint Committee on Cancer (AJCC) 8th edition guidelines
* Has not been previously treated for melanoma beyond complete surgical resection
* Has =12 weeks between final surgical resection and randomization
* Has no evidence of metastatic disease on imaging as determined by investigator
* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale or Lansky Play-Performance Scale (LPS) score =50 for participants =16 years old, or a Karnofsky Performance Scale (KPS) score =50 for participants >16 and <18 years old
* Has recovered adequately from toxicity and/or complications from surgery prior to study start
* Female participants must not be pregnant or breastfeeding, and must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment if they are women of childbearing potential (WOCBP)
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion:

* Has a known additional malignancy that is progressing or has required active antineoplastic therapy (including hormonal) within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
* WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1), anti-Programmed Cell Death Receptor Ligand 1 (PD-L1) or anti-Programmed Cell Death Receptor Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
* Has received prior systemic anti-cancer therapy for melanoma including investigational agents
* Has received a live vaccine within 30 days prior to the first dose of study treatment
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
* Has severe hypersensitivity (=Grade 3) to any excipients of pembrolizumab
* Has an active autoimmune disease that has required systemic treatment in the past 2 years
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
* Has an active infection requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of hepatitis B (defined as hepatitis B surface antigen reactive) or known active hepatitis C virus (defined as hepatitis C virus ribonucleic acid [RNA] [qualitative] is detected) infection
* Has a history of active tuberculosis (Bacillus tuberculosis)
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
* Has had an allogeneic tissue/solid organ transplant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/09/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
12/10/2033
Actual
Sample size
Target
Accrual to date
Final
976
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Melanoma Institute Australia ( Site 0856) - North Sydney
Recruitment hospital [2] 0 0
Westmead Hospital ( Site 0853) - Westmead
Recruitment hospital [3] 0 0
Cairns Base Hospital ( Site 0859) - Cairns
Recruitment hospital [4] 0 0
Tasman Oncology Research Pty Ltd ( Site 0858) - Southport
Recruitment hospital [5] 0 0
Princess Alexandra Hospital ( Site 0857) - Woolloongabba
Recruitment hospital [6] 0 0
Royal Adelaide Hospital ( Site 0861) - Adelaide
Recruitment hospital [7] 0 0
Ashford Cancer Centre Research ( Site 0860) - Kurralta Park
Recruitment hospital [8] 0 0
The Alfred Hospital ( Site 0852) - Melbourne
Recruitment hospital [9] 0 0
Fiona Stanley Hospital ( Site 0851) - Murdoch
Recruitment postcode(s) [1] 0 0
2065 - North Sydney
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4870 - Cairns
Recruitment postcode(s) [4] 0 0
4215 - Southport
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [8] 0 0
3004 - Melbourne
Recruitment postcode(s) [9] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oklahoma
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Belgium
State/province [24] 0 0
Antwerpen
Country [25] 0 0
Belgium
State/province [25] 0 0
Bruxelles-Capitale, Region De
Country [26] 0 0
Belgium
State/province [26] 0 0
Limburg
Country [27] 0 0
Belgium
State/province [27] 0 0
Oost-Vlaanderen
Country [28] 0 0
Belgium
State/province [28] 0 0
Vlaams-Brabant
Country [29] 0 0
Brazil
State/province [29] 0 0
Parana
Country [30] 0 0
Brazil
State/province [30] 0 0
Rio Grande Do Sul
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Paulo
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio de Janeiro
Country [33] 0 0
Canada
State/province [33] 0 0
Alberta
Country [34] 0 0
Canada
State/province [34] 0 0
Manitoba
Country [35] 0 0
Canada
State/province [35] 0 0
New Brunswick
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Chile
State/province [38] 0 0
Araucania
Country [39] 0 0
Chile
State/province [39] 0 0
Region M. De Santiago
Country [40] 0 0
Chile
State/province [40] 0 0
Valparaiso
Country [41] 0 0
Chile
State/province [41] 0 0
Antofagasta
Country [42] 0 0
France
State/province [42] 0 0
Bouches-du-Rhone
Country [43] 0 0
France
State/province [43] 0 0
Cote-d Or
Country [44] 0 0
France
State/province [44] 0 0
Gironde
Country [45] 0 0
France
State/province [45] 0 0
Haute-Garonne
Country [46] 0 0
France
State/province [46] 0 0
Hauts-de-Seine
Country [47] 0 0
France
State/province [47] 0 0
Herault
Country [48] 0 0
France
State/province [48] 0 0
Ille-et-Vilaine
Country [49] 0 0
France
State/province [49] 0 0
Maine-et-Loire
Country [50] 0 0
France
State/province [50] 0 0
Marne
Country [51] 0 0
France
State/province [51] 0 0
Nord
Country [52] 0 0
France
State/province [52] 0 0
Rhone
Country [53] 0 0
France
State/province [53] 0 0
Somme
Country [54] 0 0
France
State/province [54] 0 0
Val-de-Marne
Country [55] 0 0
France
State/province [55] 0 0
Paris
Country [56] 0 0
Germany
State/province [56] 0 0
Baden-Wurttemberg
Country [57] 0 0
Germany
State/province [57] 0 0
Bayern
Country [58] 0 0
Germany
State/province [58] 0 0
Niedersachsen
Country [59] 0 0
Germany
State/province [59] 0 0
Nordrhein-Westfalen
Country [60] 0 0
Germany
State/province [60] 0 0
Schleswig-Holstein
Country [61] 0 0
Germany
State/province [61] 0 0
Thuringen
Country [62] 0 0
Germany
State/province [62] 0 0
Hamburg
Country [63] 0 0
Israel
State/province [63] 0 0
Southern
Country [64] 0 0
Israel
State/province [64] 0 0
Tell Abib
Country [65] 0 0
Israel
State/province [65] 0 0
Afula
Country [66] 0 0
Israel
State/province [66] 0 0
Haifa
Country [67] 0 0
Israel
State/province [67] 0 0
Jerusalem
Country [68] 0 0
Israel
State/province [68] 0 0
Ramat Gan
Country [69] 0 0
Israel
State/province [69] 0 0
Zerifin
Country [70] 0 0
Italy
State/province [70] 0 0
Forli-Cesena
Country [71] 0 0
Italy
State/province [71] 0 0
Bari
Country [72] 0 0
Italy
State/province [72] 0 0
Bergamo
Country [73] 0 0
Italy
State/province [73] 0 0
Genova
Country [74] 0 0
Italy
State/province [74] 0 0
Milano
Country [75] 0 0
Italy
State/province [75] 0 0
Napoli
Country [76] 0 0
Italy
State/province [76] 0 0
Padova
Country [77] 0 0
Italy
State/province [77] 0 0
Roma
Country [78] 0 0
Italy
State/province [78] 0 0
Siena
Country [79] 0 0
Japan
State/province [79] 0 0
Tokyo
Country [80] 0 0
Poland
State/province [80] 0 0
Kujawsko-pomorskie
Country [81] 0 0
Poland
State/province [81] 0 0
Malopolskie
Country [82] 0 0
Poland
State/province [82] 0 0
Mazowieckie
Country [83] 0 0
Poland
State/province [83] 0 0
Podkarpackie
Country [84] 0 0
Poland
State/province [84] 0 0
Pomorskie
Country [85] 0 0
Poland
State/province [85] 0 0
Slaskie
Country [86] 0 0
Poland
State/province [86] 0 0
Wielkopolskie
Country [87] 0 0
South Africa
State/province [87] 0 0
Eastern Cape
Country [88] 0 0
South Africa
State/province [88] 0 0
Gauteng
Country [89] 0 0
South Africa
State/province [89] 0 0
Limpopo
Country [90] 0 0
South Africa
State/province [90] 0 0
Western Cape
Country [91] 0 0
Spain
State/province [91] 0 0
Gipuzkoa
Country [92] 0 0
Spain
State/province [92] 0 0
Valenciana, Comunitat
Country [93] 0 0
Spain
State/province [93] 0 0
Barcelona
Country [94] 0 0
Spain
State/province [94] 0 0
Madrid
Country [95] 0 0
Spain
State/province [95] 0 0
Sevilla
Country [96] 0 0
Switzerland
State/province [96] 0 0
Basel-Stadt
Country [97] 0 0
Switzerland
State/province [97] 0 0
Berne
Country [98] 0 0
Switzerland
State/province [98] 0 0
Geneve
Country [99] 0 0
Switzerland
State/province [99] 0 0
Grisons
Country [100] 0 0
Switzerland
State/province [100] 0 0
Sankt Gallen
Country [101] 0 0
Switzerland
State/province [101] 0 0
Ticino
Country [102] 0 0
Switzerland
State/province [102] 0 0
Vaud
Country [103] 0 0
Switzerland
State/province [103] 0 0
Wallis
Country [104] 0 0
Switzerland
State/province [104] 0 0
Zurich
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Cambridgeshire
Country [106] 0 0
United Kingdom
State/province [106] 0 0
London, City Of
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Surrey
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/\~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. Participants who complete the initial treatment of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo.

Per protocol, response/ progression or adverse events (AEs) during re-challenge/switch-over in Part 2 will not be counted towards the RFS outcome measure or safety outcome measures respectively.
Trial website
https://clinicaltrials.gov/study/NCT03553836
Trial related presentations / publications
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10;42(14):1619-1624. doi: 10.1200/JCO.23.02355. Epub 2024 Mar 7.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1.
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03553836